KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aquestive Therapeutics (AQST) Shares Outstanding (2017 - 2025)

Aquestive Therapeutics has reported Shares Outstanding over the past 9 years, most recently at $122.0 million for Q4 2025.

  • Quarterly results put Shares Outstanding at $122.0 million for Q4 2025, up 33.51% from a year ago — trailing twelve months through Dec 2025 was $122.0 million (up 33.51% YoY), and the annual figure for FY2025 was $122.0 million, up 33.51%.
  • Shares Outstanding for Q4 2025 was $122.0 million at Aquestive Therapeutics, roughly flat from $121.7 million in the prior quarter.
  • Over the last five years, Shares Outstanding for AQST hit a ceiling of $122.0 million in Q4 2025 and a floor of $36.2 million in Q1 2021.
  • Median Shares Outstanding over the past 5 years was $64.2 million (2023), compared with a mean of $71.0 million.
  • Biggest five-year swings in Shares Outstanding: grew 7.92% in 2021 and later surged 61.79% in 2024.
  • Aquestive Therapeutics' Shares Outstanding stood at $41.2 million in 2021, then surged by 32.98% to $54.8 million in 2022, then grew by 25.0% to $68.5 million in 2023, then soared by 33.39% to $91.4 million in 2024, then soared by 33.51% to $122.0 million in 2025.
  • The last three reported values for Shares Outstanding were $122.0 million (Q4 2025), $121.7 million (Q3 2025), and $99.4 million (Q2 2025) per Business Quant data.